Remarkable Efficacy of Blood Glucose and Weight by Oral Semaglutide (Rybelsus) For Short Period

Background: Authors and researchers have continued clinical practice and research of diabetes and endocrinology for long. As a glucagon-like peptide 1 receptor agonist (GLP-1RA), oral semaglutide (Rybelsus) was applied to patient with type 2 diabetes (T2D) and investigated.
Case Presentation: Case is 51-year-old male patient with T2D for 8 years. His diabetic control was exacerbated to HbA1c 8.5% in autumn 2021, and then Rybelsus was administered for increasing doses of 3mg, 7mg, and 14mg per day. The results showed improvement of HbA1c 8.5% to 7.1% and weight 96kg to 91kg for 3 months.
Discussion and conclusion: Current remarkable effect may be from the characteristic benefit of Rybelsus. It is provided per os with 50-120 ml of water in the early morning, and after that at least 30 min of fasting time period is required. As fasting time is longer, the Rybelsus concentration in the blood and clinical efficacy become higher. The case has daily habit of no breakfast for long, and fasting time was about 3-4 hours. This situation may be one of the main reasons for remarkable efficacy. Current case will become an impressive reference for clinical effect of Rybelsus in patient with T2D.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.